ETON PHARMACEUTICALS INC (ETON)

Company Profile

Eton Pharmaceuticals, Inc. engages in the development, acquisition, and commercialization of prescription drug products. The company is headquartered in Deer Park, Illinois and currently employs 30 full-time employees. The company went IPO on 2018-11-09. The firm is focused on developing and commercializing treatments for rare diseases. The firm has five commercial rare disease products: ALKINDI SPRINKLE, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous, and Nitisinone. The firm has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector. ALKINDI SPRINKLE is a granule hydrocortisone formulation designed to help provide accurate dosing for newborns and children with adrenal insufficiency. PKU GOLIKE is a next generation medical formula product engineered with the patent protected, pharmaceutical grade Physiomimic technology for the dietary management of phenylketonuria (PKU) under medical supervision. Carglumic Acid is used for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate synthase (NAGS) deficiency. Betaine Anhydrous is developed for the treatment of homocystinuria.

Company Info

ETON PHARMACEUTICALS INC

21925 W Field Pkwy Ste 235

Deer Park ILLINOIS 60010

P: 18477877361

CEO: Sean E. Brynjelsen

Employees: 30

Website: https://etonpharma.com/